A detailed history of Jpmorgan Chase & CO transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 300 shares of PRQR stock, worth $1,041. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Previous 314 4.46%
Holding current value
$1,041
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$1.64 - $2.24 $22 - $31
-14 Reduced 4.46%
300 $0
Q2 2024

Aug 12, 2024

SELL
$1.65 - $2.39 $1,945 - $2,817
-1,179 Reduced 78.97%
314 $0
Q1 2024

May 10, 2024

SELL
$1.89 - $2.85 $606 - $914
-321 Reduced 17.7%
1,493 $3,000
Q4 2023

Feb 12, 2024

SELL
$1.15 - $2.21 $167,544 - $321,977
-145,691 Reduced 98.77%
1,814 $3,000
Q3 2023

Nov 14, 2023

SELL
$1.3 - $1.77 $42,759 - $58,218
-32,892 Reduced 18.23%
147,505 $191,000
Q2 2023

Aug 11, 2023

SELL
$1.62 - $2.32 $68,329 - $97,855
-42,179 Reduced 18.95%
180,397 $292,000
Q1 2023

May 11, 2023

BUY
$1.99 - $3.66 $439,348 - $808,047
220,778 Added 12279.09%
222,576 $474,000
Q4 2022

Feb 13, 2023

SELL
$0.8 - $3.7 $2,426 - $11,222
-3,033 Reduced 62.78%
1,798 $7,000
Q3 2022

Nov 14, 2022

SELL
$0.74 - $0.89 $710,313 - $854,295
-959,883 Reduced 99.5%
4,831 $4,000
Q2 2022

Aug 11, 2022

SELL
$0.56 - $1.0 $7,324 - $13,080
-13,080 Reduced 1.34%
964,714 $750,000
Q1 2022

May 11, 2022

BUY
$0.9 - $8.39 $241,483 - $2.25 Million
268,315 Added 37.82%
977,794 $885,000
Q4 2021

Feb 10, 2022

SELL
$6.58 - $8.44 $1.59 Million - $2.04 Million
-241,581 Reduced 25.4%
709,479 $5.68 Million
Q3 2021

Nov 12, 2021

BUY
$5.16 - $8.47 $4.91 Million - $8.06 Million
951,060 New
951,060 $7.96 Million

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $248M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.